83 related articles for article (PubMed ID: 18200050)
1. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sézary cells.
van Kester MS; Out-Luiting JJ; von dem Borne PA; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2008 Jul; 128(7):1691-5. PubMed ID: 18200050
[TBL] [Abstract][Full Text] [Related]
2. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
3. Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.
van der Fits L; Out-Luiting JJ; Tensen CP; Zoutman WH; Vermeer MH
J Invest Dermatol; 2014 Oct; 134(10):2639-2647. PubMed ID: 24756111
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells.
Brouwer IJ; Out-Luiting JJ; Vermeer MH; Tensen CP
Biochem Biophys Rep; 2020 Dec; 24():100832. PubMed ID: 33102814
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
6. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
[TBL] [Abstract][Full Text] [Related]
7. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
8. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
9. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.
van der Fits L; Out-Luiting JJ; van Leeuwen MA; Samsom JN; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Feb; 132(2):440-7. PubMed ID: 21938013
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling.
Sun C; Zhang M; Shan X; Zhou X; Yang J; Wang Y; Li-Ling J; Deng Y
J Cancer Res Clin Oncol; 2010 Apr; 136(4):603-10. PubMed ID: 19816711
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).
Michel L; Dupuy A; Jean-Louis F; Sors A; Poupon J; Viguier M; Musette P; Dubertret L; Degos L; Dombret H; Bachelez H
J Invest Dermatol; 2003 Oct; 121(4):881-93. PubMed ID: 14632209
[TBL] [Abstract][Full Text] [Related]
12. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.
Shi X; Franko B; Frantz C; Amin HM; Lai R
Br J Haematol; 2006 Oct; 135(1):26-32. PubMed ID: 16939498
[TBL] [Abstract][Full Text] [Related]
13. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
14. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I.
Graness A; Poli V; Goppelt-Struebe M
Biochem Pharmacol; 2006 Jun; 72(1):32-41. PubMed ID: 16707113
[TBL] [Abstract][Full Text] [Related]
15. The induction of G2/M cell-cycle arrest and apoptosis by cucurbitacin E is associated with increased phosphorylation of eIF2alpha in leukemia cells.
Li Y; Wang R; Ma E; Deng Y; Wang X; Xiao J; Jing Y
Anticancer Drugs; 2010 Apr; 21(4):389-400. PubMed ID: 20110807
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway.
Dong Y; Lu B; Zhang X; Zhang J; Lai L; Li D; Wu Y; Song Y; Luo J; Pang X; Yi Z; Liu M
Carcinogenesis; 2010 Dec; 31(12):2097-104. PubMed ID: 20732905
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
van Doorn R; Dijkman R; Vermeer MH; Out-Luiting JJ; van der Raaij-Helmer EM; Willemze R; Tensen CP
Cancer Res; 2004 Aug; 64(16):5578-86. PubMed ID: 15313894
[TBL] [Abstract][Full Text] [Related]
18. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer.
Song J; Liu H; Li Z; Yang C; Wang C
Oncol Rep; 2015 Apr; 33(4):1867-71. PubMed ID: 25625299
[TBL] [Abstract][Full Text] [Related]
20. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
